Joan Blade

Joan Blade

UNVERIFIED PROFILE

Are you Joan Blade?   Register this Author

Register author
Joan Blade

Joan Blade

Publications by authors named "Joan Blade"

Are you Joan Blade?   Register this Author

100Publications

4198Reads

38Profile Views

Six-2 glomerular expression for the prediction of renal outcome in systemic amyloidosis.

Amyloid 2019;26(sup1):97-98

a Department of Nephrology, Amyloidosis and Myeloma Unit, Hospital Clinic, University of Barcelona , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13506129.2019.1582483DOI Listing
January 2019

M-protein-related disorders: MGCS.

Blood 2018 10;132(14):1464-1465

Institut d'Investigacions Biomèdiques August Pi i Sunyer.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-07-865642DOI Listing
October 2018

The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.

Leukemia 2018 09 23;32(9):2082-2094. Epub 2018 May 23.

Departments of Hematology, Amyloidosis and Myeloma Unit. Hospital Clínic, IDIBAPS., University of Barcelona., Villarroel 170, 08036, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0156-3DOI Listing
September 2018

Testicular plasmacytoma: unique location or circumstantial presentation?

Leuk Lymphoma 2018 08 9;59(8):1769-1771. Epub 2018 Jan 9.

a Division of Hematology , Mayo Clinic , Rochester , MN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1421763DOI Listing
August 2018

Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency.

J Clin Oncol 2018 07 31;36(20):2012-2016. Epub 2018 May 31.

Joan Bladé, Laura Rosiñol, María Teresa Cibeira, and Carlos Fernández de Larrea, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6419DOI Listing
July 2018

Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

Leukemia 2018 06 2;32(6):1427-1434. Epub 2018 Feb 2.

Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-018-0013-4
Publisher Site
http://dx.doi.org/10.1038/s41375-018-0013-4DOI Listing
June 2018

Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.

Amyloid 2018 Jun 26;25(2):79-85. Epub 2018 Feb 26.

a Amyloidosis and Myeloma Unit, Department of Hematology , Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona , Barcelona , Spain.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13506129.2018.1
Publisher Site
http://dx.doi.org/10.1080/13506129.2018.1443439DOI Listing
June 2018

Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.

J Immunol 2018 04 12;200(8):2581-2591. Epub 2018 Mar 12.

Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, 08036 Barcelona, Spain;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1701622DOI Listing
April 2018

Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.

Br J Haematol 2017 12 8;179(5):849-851. Epub 2016 Sep 8.

Amyloidosis and Myeloma Unit, Department of Haematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14266DOI Listing
December 2017

Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.

Amyloid 2017 Dec 20;24(4):245-252. Epub 2017 Oct 20.

a Department of Hematology , Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13506129.2017.1390451DOI Listing
December 2017

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

J Clin Oncol 2017 Sep 12;35(25):2900-2910. Epub 2017 May 12.

Juan-Jose Lahuerta, Maria-Teresa Cedena, Joaquin Martinez-Lopez, and María-Luisa Martín-Ramos, Hospital 12 de Octubre, CIBERONC; Raquel de Paz, Hospital Universitario La Paz; Rafael Martinez, Hospital Clínico San Carlos; Adrian Alegre, Hospital Universitario La Princesa, Madrid; Bruno Paiva and Jesus F. San-Miguel, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona; Laura Rosiñol, and Joan Blade, Hospital Clínic de Barcelona, Barcelona; Maria-Belen Vidriales, Noemi Puig, Norma C. Gutierrez, Alejandro Martin, and María-Victoria Mateos, Hospital Universitario de Salamanca Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBERONC; Alberto Orfao, Servicio General de Citometría-NUCLEOS, Centro de Investigación del Cancer (IBMCC-USAL, CSIC), IBSAL and Department of Medicine, Universidad de Salamanca, CIBERONC, Salamanca; Lourdes Cordón and Javier De la Rubia, Hospital Universitario y Politécnico La Fe; Ana-Isabel Teruel, Hospital Clínico de Valencia, Valencia; Albert Oriol, Hospital Germans Trias i Pujol, Badalona; María-Asunción Echeveste, Hospital de Donostia, San Sebastian; Felipe de Arriba, Hospital Morales Meseguer, Murcia; Miguel T. Hernandez, Hospital Universitario de Canarias, Tenerife; Luis Palomera, Hospital Universitario Lozano Blesa, Zaragoza, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568033PMC
September 2017

Impact of Autologous Stem Cell Transplantation on the Incidence and Outcome of Oligoclonal Bands in Patients with Light-Chain Amyloidosis.

Biol Blood Marrow Transplant 2017 Aug 18;23(8):1269-1275. Epub 2017 Apr 18.

Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791173040
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2017.04.012DOI Listing
August 2017

Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.

Med Clin (Barc) 2017 06 22;148(11):517-523. Epub 2017 Mar 22.

Grupo Español de Mieloma (GEM)/PETHEMA; Clínica Universidad de Navarra, Pamplona, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.medcli.2017.02.012DOI Listing
June 2017

Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.

Br J Haematol 2016 Nov 19;175(3):448-456. Epub 2016 Jul 19.

Clinical and Translational Medicine, Clínica Universidad de Navarra - CIMA (Centro de Investigación Médica Aplicada) - IdiSNA (Instituto de Investigación Sanitaria de Navarra), Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14263DOI Listing
November 2016

Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.

Clin Lymphoma Myeloma Leuk 2016 Jun 27;16(6):e71-7. Epub 2016 Feb 27.

Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, and Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.02.034DOI Listing
June 2016

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2015 Dec 30;21(12):2039-2051. Epub 2015 Sep 30.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757494PMC
December 2015

Treatment for patients with newly diagnosed multiple myeloma in 2015.

Blood Rev 2015 Nov 12;29(6):387-403. Epub 2015 Jun 12.

Clínica Universidad de Navarra/Centro de Investigación Médica Aplicada (CIMA), Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2015.06.001DOI Listing
November 2015

Upfront CyBorD in AL amyloidosis.

Blood 2015 Jul;126(5):564-6

INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-648113DOI Listing
July 2015

Extramedullary disease in multiple myeloma in the era of novel agents.

Br J Haematol 2015 Jun 30;169(6):763-5. Epub 2015 Mar 30.

Amyloidosis and Myeloma Unit, Haematology Department, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13384DOI Listing
June 2015

T1 mapping: characterisation of myocardial interstitial space.

Insights Imaging 2015 Apr 26;6(2):189-202. Epub 2014 Nov 26.

Radiology Department. Hospital Clinic, University of Barcelona, Barcelona, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13244-014-0366-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376813PMC
April 2015

How I treat relapsed myeloma.

Blood 2015 Mar 13;125(10):1532-40. Epub 2015 Jan 13.

Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona, Spain; and Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-10-551531DOI Listing
March 2015

A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.

Oncotarget 2015 Jan;6(3):1874-83

Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359338PMC
http://dx.doi.org/10.18632/oncotarget.2761DOI Listing
January 2015

Extramedullary myeloma spread triggered by surgical procedures: an emerging entity?

Acta Haematol 2014 10;132(1):36-8. Epub 2014 Jan 10.

Amyloidosis and Myeloma Unit, Hematology Department, IDIBAPS, Barcelona Hospital Clinic, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000354833DOI Listing
September 2014

Issues of front-line therapy for multiple myeloma--the standard of care.

Leuk Lymphoma 2014 Sep 20;55(9):1959-61. Epub 2014 Mar 20.

Amyloid and Myeloma Unit, Hematology Department, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi I Sunyer) Hospital Clínic , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.896460DOI Listing
September 2014

European perspective on multiple myeloma treatment strategies in 2014.

Oncologist 2014 Aug 25;19(8):829-44. Epub 2014 Jul 25.

Department of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria; Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands; Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; Department of Hematology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain; Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Ospedale Molinette, Turin, Italy; Institute of Hematology and Medical Oncology, Seragnoli, Bologna, Italy; Haemato-Oncology Unit, Royal Marsden Hospital, Surrey, United Kingdom; Hematology Service, University Hospital La Fe, Valencia, Spain; Department of Hematology, University Hospital, Leuven, Belgium; Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany; Service d'Hématologie, Centre Hospitalier Universitaire, Lille, France; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; University Hospital, Nantes, France; Karolinska Institute, Stockholm, Sweden; Department of Hematology, Center Lillebaelt, University of Southern Denmark, Odense, Denmark; Clinica Universidad de Navarra, Centro Investigaciones Medicas Aplicada, Pamplona, Spain; Department of Hemato-oncology, University of Ostrava, Ostrava, Czech Republic; University of Giessen, Giessen, Germany.

View Article

Download full-text PDF

Source
http://szpiczak.org/lang/aktualnosci/publikacje/rok_2014/The
Web Search
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122482PMC
August 2014

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

J Clin Oncol 2014 Jul 2;32(20):2173-80. Epub 2014 Jun 2.

Philippe Moreau, University Hospital Hôtel-Dieu; Jean-Luc Harousseau, Centre Rene Gauducheau, Nantes; Michel Attal, Centre Hospitalier Universitaire (CHU) Toulouse; Hervé Avet-Loiseau, CHU Rangueil, Toulouse; Gerald Marit, University Hospital of Bordeaux, Bordeaux; Cyrille Hulin, CHU Nancy, Nancy; Thierry Facon, Hopital Claude Huriez; Xavier Leleu, University Hospital of Lille, Lille; Denis Caillot, CHU Dijon, Dijon; Lotfi Benboubker, Centre Hospitalier Régional Universitaire Tours, Tours; Jean-Yves Mary, University Hospital Paris Saint-Louis, Paris, France; Michele Cavo, Annalisa Pezzi, and Elena Zamagni, Seràgnoli Institute of Hematology, Bologna; Antonio Palumbo, University of Torino, Torino; Maria Teresa Petrucci, Sapienza University of Rome, Rome; Francesca Patriarca, University Hospital, Udine, Italy; Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Bronno van der Holt, Daniel den Hoed Cancer Center at Erasmus Medical Center, Rotterdam; Henk Lokhorst, University Medical Center Utrecht, Utrecht, the Netherlands; Hartmut Goldschmidt, Universitätsklinikum Heidelberg; Kai Neben, University of Heidelberg, Heidelberg, Germany; Laura Rosinol and Joan Bladé, Hospital Clinic, Barcelona; Juan Jose Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jesus san Miguel, University of Salamanca; Norma Gutierrez, Hospital Universitario de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879712PMC
July 2014

The comprehensive clinical management of multiple myeloma and related-plasma cell disorders.

Expert Rev Hematol 2014 Feb;7(1):1-3

RJ Corman Professor of Medicine, Harvard Medical School Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.882763DOI Listing
February 2014

Response evaluation and monitoring of multiple myeloma.

Expert Rev Hematol 2014 Feb;7(1):33-42

Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.876899DOI Listing
February 2014

Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma.

Ann Hematol 2014 Jan 12;93(1):107-11. Epub 2013 Nov 12.

Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-013-1942-7DOI Listing
January 2014

Acquired Fanconi syndrome secondary to monoclonal gammopathies: a case series from a single center.

Clin Lymphoma Myeloma Leuk 2013 Oct 15;13(5):614-8. Epub 2013 Jun 15.

Department of Hematology, Amyloid and Myeloma Unit, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.04.008DOI Listing
October 2013

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

J Clin Oncol 2013 Oct 9;31(29):3696-703. Epub 2013 Sep 9.

Jesús F. San-Miguel and María Victoria Mateos, Servicio e Hematologia, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Institut de Bilogia Molecular de Barcelona (Universidad de Salamanca-Spanish National Research Council), Salamanca; Joan Bladé, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; David Siegel, Hackensack University Medical Center, Hackensack; Kaushal K. Mishra and Song Mu, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Andreas Günther, University of Kiel, Kiel; Orhan Sezer, Charité Universitätsmedizin Berlin, Berlin, Germany; Richard LeBlanc, Maisonneuve-Rosemont Hospital, Montreal, Quebec; Heather Sutherland, Vancouver General Hospital, Vancouver, British Columbia, Canada; and Monika Sopala and Priscille M. Bourquelot, Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.7068DOI Listing
October 2013

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

J Clin Oncol 2013 Sep 29;31(26):3279-87. Epub 2013 Jul 29.

Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Henk M. Lokhorst, Utrecht Medical Center, Utrecht, the Netherlands; Hartmut Goldschmidt, University Hospital of Heidelberg, Heidelberg, Germany; Laura Rosiñol, Joan Bladé, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Michele Cavo, Paola Tacchetti, Elena Zamagni, Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy; Michel Attal, Hopital Purpan, Toulouse; Philippe Moreau, University Hospital, Nantes, France; Avinash Desai, Janssen Global Services; Kevin Liu, Janssen Research and Development, Raritan, NJ; Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA; Andrew Cakana, Janssen Research and Development, High Wycombe, United Kingdom; Helgi van de Velde, Janssen Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.4626DOI Listing
September 2013

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

N Engl J Med 2013 Aug;369(5):438-47

Hospital Universitario de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1300439DOI Listing
August 2013

Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution.

Haematologica 2013 Jul 3;98(7):1142-6. Epub 2013 May 3.

Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2013.084350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696619PMC
July 2013

Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib.

Leuk Res 2013 Jun 8;37(6):641-6. Epub 2013 Feb 8.

Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, José Carreras Leukaemia Research Institute, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.01.013DOI Listing
June 2013

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Br J Haematol 2013 Mar 7;160(5):649-59. Epub 2013 Jan 7.

Department of Cellular Biotechnology and Haematology, Sapienza University of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12198DOI Listing
March 2013

Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.

Eur J Haematol 2012 Oct 10;89(4):340-4. Epub 2012 Jul 10.

Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2012.01821.xDOI Listing
October 2012

Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective.

Adv Chronic Kidney Dis 2012 Sep;19(5):312-23

Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ackd.2012.07.001DOI Listing
September 2012

Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.

Biol Blood Marrow Transplant 2012 Jul 16;18(7):1076-9. Epub 2012 Mar 16.

Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2012.03.004DOI Listing
July 2012

Incorporating monoclonal antibodies into the therapy of multiple myeloma.

J Clin Oncol 2012 Jun 30;30(16):1904-6. Epub 2012 Jan 30.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.40.4178DOI Listing
June 2012

Novel approaches for reducing free light chains in patients with myeloma kidney.

Nat Rev Nephrol 2012 Feb 21;8(4):234-43. Epub 2012 Feb 21.

Renal Institute of Birmingham, University Hospital Birmingham and University of Birmingham, Birmingham, UK. c.a.hutchison@ bham.ac.uk

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneph.2012.14DOI Listing
February 2012